Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zilucoplan - UCB

Next Previous
Drug Profile

Zilucoplan - UCB

Alternative Names: RA 101495; RA101495 SC; ZILBRYSQ; Zilbrysq; ZLP-AI

Latest Information Update: 14 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ra Pharmaceuticals
  • Developer Ra Pharmaceuticals; UCB
  • Class Antianaemics; Antivirals; Cyclic peptides; Lactams; Macrocyclic compounds; Urologics
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myasthenia gravis
  • Phase III COVID 2019 infections
  • Phase II/III Amyotrophic lateral sclerosis
  • Discontinued Haemolytic uraemic syndrome; Immune-mediated necrotising myopathy; Lupus nephritis; Paroxysmal nocturnal haemoglobinuria; Respiratory insufficiency; Unspecified

Most Recent Events

  • 09 Jul 2025 UCB Biopharma initiates a phase I trial (In volunteers) in USA(SC, Injection)(NCT06961747)
  • 08 May 2025 UCB Biopharma plans a phase I trial (In volunteers) (SC, Injection)(NCT06961747)
  • 05 Apr 2025 Updated adverse event and efficacy data from a phase III trial in Myasthenia gravis was presented at the 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top